Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

New horizons in pulmonary arterial hypertension management

Vallerie McLaughlin, Gérald Simonneau, Nazzareno Galiè, Lewis J. Rubin
European Respiratory Review 2014 23: 408-409; DOI: 10.1183/09059180.00007614
Vallerie McLaughlin
1Dept of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France. 3AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, Service de Pneumologie et Réanimation Respiratoire, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. 4UMR-S 999, INSERM and Université Paris-Sud, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 5Dept of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy. 6Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vmclaugh@umich.edu
Gérald Simonneau
1Dept of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France. 3AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, Service de Pneumologie et Réanimation Respiratoire, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. 4UMR-S 999, INSERM and Université Paris-Sud, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 5Dept of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy. 6Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA, USA
1Dept of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France. 3AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, Service de Pneumologie et Réanimation Respiratoire, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. 4UMR-S 999, INSERM and Université Paris-Sud, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 5Dept of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy. 6Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA, USA
1Dept of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France. 3AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, Service de Pneumologie et Réanimation Respiratoire, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. 4UMR-S 999, INSERM and Université Paris-Sud, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 5Dept of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy. 6Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nazzareno Galiè
1Dept of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France. 3AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, Service de Pneumologie et Réanimation Respiratoire, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. 4UMR-S 999, INSERM and Université Paris-Sud, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 5Dept of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy. 6Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lewis J. Rubin
1Dept of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Université Paris-Sud, Faculté de Médecine, Le Kremlin-Bicêtre, France. 3AP-HP, Centre de Référence de l’Hypertension Pulmonaire Sévère, Département Hospitalo-Universitaire (DHU) Thorax Innovation, Service de Pneumologie et Réanimation Respiratoire, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France. 4UMR-S 999, INSERM and Université Paris-Sud, Laboratoire d’Excellence (LabEx) en Recherche sur le Médicament et l’Innovation Thérapeutique (LERMIT), Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France. 5Dept of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy. 6Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Significant developments have been made in the management of pulmonary arterial hypertension (PAH) over the past year. These include an increased understanding of the need for earlier detection and treatment, changing disease characteristics, the continuing development of new treatment options and an increasing perception of the specific challenges that patients with PAH face at each stage of illness. Notably, an updated treatment algorithm from the 5th World Symposium on Pulmonary Hypertension has been published [1], reflecting recent changes in available evidence. The articles in this issue of the European Respiratory Review encompass the breadth of these issues and are based on presentations from the 13th International Pulmonary Hypertension Forum held in April 2014 in Lisbon, Portugal. These articles not only provide a snapshot of the current understanding but also offer a forward-looking view to new horizons in PAH management.

Progressive failure of the right ventricle due to increased pulmonary vascular resistance is a significant cause of morbidity and mortality in patients with PAH. In the article by Naeije and Manes [2], the measurement and pathobiology of the interaction between the right ventricle and the arterial system, the role of diastolic function, and the influence of the left ventricle function on right ventricular activity are discussed.

In examining the clinical and disease characteristics of patients living with PAH, the historical importance of registry data cannot be overstated. As the body of evidence from registries continues to build, it offers a window into changes in patient populations and characteristics over time. In the article by Hoeper and Gibbs [3], new trends in PAH demographics and patient subsets, the reasons for these changes, and the potential implications for disease management are identified.

Children with PAH are another distinct subset of patients requiring a tailored approach to diagnosis and treatment [4, 5]. Treatment of PAH in children is particularly challenging due to difficulties of evaluating treatment efficacy in appropriately designed clinical trials and the limited evidence currently available for PAH drugs in this population. In the article by Beghetti and Berger [6], these challenges are discussed in the context of current options for disease classification, available data from registries and clinical trials, and the authors’ own clinical experience.

While historically, combination therapy has been widely used in PAH management, support for this use has been primarily based on expert opinion, registry data or prior clinical experience. However, as evidence from clinical trials and real-world data increase, it provides a new context in which the role and importance of combination therapy must be re-evaluated. A recent example of this change is reflected in the change in recommendation grade for sequential combination therapy in the updated treatment algorithm [1], which is a result of trials such as SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome) [7] and PATENT-1 (Pulmonary Arterial Hypertension Soluble Guanylate Cyclase-Stimulator Trial 1) [8]. The article by Ghofrani and Humbert [9] offers a comprehensive summary of the latest available data in combination therapy, and the resultant insights and implications for current and future treatment.

The use of upfront combination therapy is now recommended in patients who are in World Health Organization functional class III/IV, albeit with a lower level of recommendation than monotherapy and sequential combination therapy [1]. A recent pilot study showed promise in a small group of patients with severe PAH [10, 11]. This treatment approach, and the multifaceted reality of treating severe PAH, is the focus of a case-based review by Sitbon [12], which charts the progress of a patient with severe PAH associated with mixed connective tissue disease who received upfront triple combination therapy for PAH along with immunosuppresive therapy.

The successful treatment of patients with severe PAH requires both timely treatment changes (in the form of transitioning to intravenous or subcutaneous pharmacotherapy in response to disease worsening) and managing the transition, when necessary, to lung transplantation. This requires knowledge of the treatments available to patients with severe PAH, an understanding of the level of clinical assessment and examination required, and an awareness of the techniques that can be employed to bridge patients to transplantation. The article by Corris and Degano [13] offers an excellent summary of these elements.

The need to consider transplantation highlights how the long-term prognosis for patients with this disease remains poor, in spite of continued advances in treatment options [14]. In this context, the expectations placed on treatment by physicians and patients may differ. What constitutes treatment success for the patient? And does this expectation match that of the treating physician? What level of patient support is required beyond diagnosis and pharmacotherapy? Howard et al. [15] discuss these questions from both a physician and patient perspective, offering a unique insight into the essential requirements for improved patient support and decision making.

Together, the articles in this issue of European Respiratory Review highlight the multifaceted nature of PAH and the progress that has been made in managing this difficult disease, through registries and randomised controlled trials. These articles also highlight the importance that the exchange and communication of ideas amongst physicians and patients can play in recognising and moving towards new horizons in PAH treatment.

Acknowledgments

Medical writing support was provided by Nason Ma'ani (apothecom scopemedical ltd, Sevenoaks, UK), which was funded by Actelion Pharmaceuticals Ltd (Allschwil, Switzerland).

Footnotes

  • Provenance: Publication of this peer-reviewed article was sponsored by Actelion Pharmaceuticals Ltd, Allschwil, Switzerland (principal sponsor, European Respiratory Review issue 134).

  • Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

  • Received August 29, 2014.
  • Accepted September 1, 2014.
  • ©ERS 2014

ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Galiè N,
    2. Corris PA,
    3. Frost A,
    4. et al
    . Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62 Suppl. 25:D60 D72 .
    OpenUrlCrossRefPubMed
  2. ↵
    1. Naeije R,
    2. Manes A
    . The right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 476–487.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Hoeper MM,
    2. Gibbs JSR
    . The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev 2014; 23: 450–457.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Ivy DD,
    2. Abman SH,
    3. Barst RJ,
    4. et al
    . Pediatric pulmonary hypertension. J Am Coll Cardiol 2013; 62 Suppl. 25:D117 D126 .
    OpenUrlCrossRefPubMed
  5. ↵
    1. Berger RM
    . Pulmonary hypertension: smaller kids, smaller steps. Lancet Respir Med 2014; 2: 348–350.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Beghetti M,
    2. Berger RMF
    . The challenges in paediatric pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 498–504.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Pulido T,
    2. Adzerikho I,
    3. Channick RN,
    4. et al
    . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ghofrani HA,
    2. Galiè N,
    3. Grimminger F,
    4. et al
    . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330–340.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ghofrani H-A,
    2. Humbert M
    . The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev 2014; 23: 469–475.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Sitbon O,
    2. Jaïs X,
    3. Savale L,
    4. et al
    . Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014; 43: 1691–1697.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. McGoon MD
    . Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass? Eur Respir J 2014; 43: 1556–1559.
    OpenUrlFREE Full Text
  12. ↵
    1. Sitbon O,
    2. Bertoletti L
    . Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment. Eur Respir Rev 2014; 23: 505–509.
    OpenUrlFREE Full Text
  13. ↵
    1. Corris P,
    2. Degano B
    . Severe pulmonary arterial hypertension: treatment options and the bridge to transplantion. Eur Respir Rev 2014; 23: 488–497.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Barst RJ,
    2. Chung L,
    3. Zamanian RT,
    4. et al
    . Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry. Chest 2013; 144: 160–168.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Howard LS,
    2. Ferrari P,
    3. Mehta S
    . Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet? Eur Respir Rev 2014; 23: 458–468.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 23 Issue 134 Table of Contents
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
New horizons in pulmonary arterial hypertension management
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
New horizons in pulmonary arterial hypertension management
Vallerie McLaughlin, Gérald Simonneau, Nazzareno Galiè, Lewis J. Rubin
European Respiratory Review Dec 2014, 23 (134) 408-409; DOI: 10.1183/09059180.00007614

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
New horizons in pulmonary arterial hypertension management
Vallerie McLaughlin, Gérald Simonneau, Nazzareno Galiè, Lewis J. Rubin
European Respiratory Review Dec 2014, 23 (134) 408-409; DOI: 10.1183/09059180.00007614
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs
  • Sex and gender in lung health and disease
  • Chronic hypersensitivity pneumonitis: a frequently fatal disease
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2022 by the European Respiratory Society